CGEM
Cullinan Therapeutics Inc.
$7.49
-$0.32(-4.10%)
58
Overall
60
Value
83
Tech
31
Quality
Market Cap
$366.26M
Volume
418.34K
52W Range
$5.68 - $17.50
Target Price
$26.88
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $18.9M | $100.0K | $500.0K | -- | ||
| Total Revenue | $18.9M | $100.0K | $500.0K | -- | ||
| GROSS PROFIT | ||||||
| Gross Profit | $18.9M | $100.0K | $500.0K | -- | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $86.9M | $132.1M | $190.6M | $196.9M | ||
| Research & Development | $57.8M | $91.9M | $148.2M | $142.9M | ||
| Research Expense | $57.8M | $91.9M | $148.2M | $142.9M | ||
| Selling, General & Administrative | $29.1M | $40.2M | $42.5M | $54.0M | ||
| General & Administrative Expenses | $29.1M | $40.2M | $42.5M | $54.0M | ||
| Salaries & Wages | $24.4M | $28.0M | $30.4M | $37.8M | ||
| Depreciation & Amortization | $100.0K | $100.0K | $300.0K | $300.0K | ||
| Depreciation & Amortization | $100.0K | $100.0K | $300.0K | $300.0K | ||
| Other Operating Expenses | -- | -- | $1.7M | -- | ||
| OPERATING INCOME | ||||||
| Operating income | $-68.0M | $144.6M | $-191.1M | $-196.9M | ||
| EBITDA | $-64.3M | $-132.0M | $-179.1M | $-182.6M | ||
| NON-OPERATING ITEMS | ||||||
| Intinc | $477.0K | $6.6M | $21.6M | $29.7M | ||
| Net Non-Operating Interest Income/Expense | $477.0K | $6.6M | $21.6M | $29.7M | ||
| Other Income/Expense | $8.0K | $276.8M | $-239.0K | $199.0K | ||
| Other Special Charges | $-8.0K | $57.0K | $239.0K | $-199.0K | ||
| SPECIAL ITEMS | ||||||
| Other Impairment Of Capital Assets | -- | -- | $440.0K | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-67.5M | $-132.1M | $-169.2M | $-167.5M | ||
| Pre-Tax Income | $-67.5M | $151.3M | $-169.2M | $-167.5M | ||
| INCOME TAX | ||||||
| Tax Provision | -- | $42.1M | $-14.1M | $117.0K | ||
| NET INCOME | ||||||
| Net Income | $-65.6M | $111.2M | $-153.2M | $-167.4M | ||
| Net Income (Continuing Operations) | $-65.6M | $109.2M | $-155.1M | $-167.6M | ||
| Net Income (Discontinued Operations) | $-65.6M | $111.2M | $-153.2M | $-167.4M | ||
| Net Income (Common Stockholders) | $-65.6M | $111.2M | $-153.2M | $-167.4M | ||
| Normalized Income | $-53.3M | -- | -- | $-165.8M | ||
| TOTALS | ||||||
| Total Expenses | $86.9M | $132.1M | $190.6M | $196.9M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $43.1M | $45.2M | $41.5M | -- | ||
| Average Shares Outstanding (Diluted) | -- | $46.6M | $41.5M | -- | ||
| Shares Outstanding | $44.6M | $39.3M | $43.1M | $58.5M | ||
| Basic EPS | $-1.52 | $2.46 | $-3.69 | -- | ||
| Basic EPS (Continuing Operations) | $-1.52 | $2.46 | $-3.69 | -- | ||
| Diluted EPS | $-1.52 | $2.38 | $-3.69 | -- | ||
| Diluted EPS (Continuing Operations) | -- | $2.38 | $-3.69 | -- | ||
| OTHER METRICS | ||||||
| Minority Interests | $1.9M | $2.0M | $1.9M | $192.0K | ||
| Other Gand A | $29.1M | $40.2M | $42.5M | $54.0M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CGEM | $7.49 | -4.1% | 418.34K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cullinan Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW